Catalyst Pharmaceuticals (NASDAQ:CPRX) Upgraded at StockNews.com

StockNews.com upgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) from a buy rating to a strong-buy rating in a research note published on Friday morning.

CPRX has been the subject of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, November 8th. Stephens initiated coverage on Catalyst Pharmaceuticals in a research note on Monday, November 18th. They issued an “overweight” rating and a $35.00 price objective for the company. Finally, Truist Financial boosted their target price on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $31.14.

Catalyst Pharmaceuticals Stock Down 1.0 %

NASDAQ CPRX opened at $21.31 on Friday. The firm has a market cap of $2.54 billion, a price-to-earnings ratio of 18.06, a price-to-earnings-growth ratio of 3.35 and a beta of 0.79. The business has a 50-day moving average price of $21.80 and a 200-day moving average price of $19.77. Catalyst Pharmaceuticals has a twelve month low of $13.12 and a twelve month high of $24.27.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 12,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total transaction of $272,640.00. Following the sale, the insider now directly owns 51,391 shares in the company, valued at $1,167,603.52. This represents a 18.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Steve Miller sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total value of $1,096,500.00. Following the sale, the insider now owns 686,996 shares in the company, valued at approximately $15,065,822.28. This trade represents a 6.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 79,500 shares of company stock worth $1,754,140 over the last ninety days. Company insiders own 11.00% of the company’s stock.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the business. Dimensional Fund Advisors LP raised its holdings in shares of Catalyst Pharmaceuticals by 9.6% in the second quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company’s stock worth $46,479,000 after buying an additional 263,099 shares during the period. Pacer Advisors Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 130,918.8% in the second quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company’s stock worth $45,968,000 after buying an additional 2,965,310 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Catalyst Pharmaceuticals by 15.2% in the second quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company’s stock worth $33,702,000 after buying an additional 287,300 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 4.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,167,743 shares of the biopharmaceutical company’s stock worth $23,215,000 after buying an additional 50,804 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in shares of Catalyst Pharmaceuticals by 2.1% in the second quarter. Bank of New York Mellon Corp now owns 834,415 shares of the biopharmaceutical company’s stock worth $12,925,000 after buying an additional 16,960 shares during the period. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.